ClinicalTrials.gov
ClinicalTrials.gov Menu

ABSORICA in Patients With Severe Recalcitrant Nodular Acne

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02457520
Recruitment Status : Completed
First Posted : May 29, 2015
Last Update Posted : November 5, 2018
Sponsor:
Information provided by (Responsible Party):
Sun Pharmaceutical Industries Limited

Brief Summary:

This is an uncontrolled, open-label study being conducted in approximately 200 healthy males, non-pregnant, non-nursing females, age 12 to 45 years, with severe recalcitrant nodular acne.

ABSORICA® (isotretinoin) capsules 0.5 mg/kg/day will be administered for 4 weeks followed by 1.0 mg/kg/day for 16 weeks. Female subjects consenting to use two forms of birth control or abstinence are included.


Condition or disease Intervention/treatment Phase
Acne Drug: Isotretinoin Phase 4

Detailed Description:

This study is designed to collect efficacy, safety, and quality of life (QOL) data from subjects who receive Absorica® without food. The study will investigate the treatment efficacy, frequency of relapse once the treatment has been discontinued, quality of life during the active treatment and during a 2-year post treatment period and the overall safety of treatment with Absorica®.

This is a single-arm, open-label study consisting of 2 phases: a 20-week (5-month) open-label Active Treatment Period (ATP) and a 104-week (2-year) post treatment period (PTP). The total study duration is to be 124 weeks, excluding a screening period. During the ATP, after week 2 visit, visits will be scheduled at 4-week intervals for a total of 8 visits (1 screening visit, 1 baseline visit, and 6 on-study visits). During the PTP, the first visit will be 4 weeks after End of Treatment (EOT), the second visit will be 12 weeks after EOT, and subsequent visits will be scheduled at 26-week (± 2 weeks) intervals for a total of 6 visits.


Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 200 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: An Open-label Study Evaluating the Long-term Efficacy, Quality of Life, and Safety of ABSORICA® (Isotretinoin) Capsules Administered Without Food in Patients With Severe Recalcitrant Nodular Acne
Actual Study Start Date : January 21, 2015
Actual Primary Completion Date : April 2018
Actual Study Completion Date : April 2018

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Acne

Arm Intervention/treatment
Experimental: Single treatment arm
ABSORICA® (isotretinoin) capsules 0.5 mg/kg/day for 4 weeks followed by 1.0 mg/kg/day for 16 weeks.
Drug: Isotretinoin
ABSORICA® (isotretinoin) capsules 0.5 mg/kg/day for 4 weeks followed by 1.0 mg/kg/day for 16 weeks
Other Name: ABSORICA




Primary Outcome Measures :
  1. Quality of life (QOL) of subjects who are taking Absorica® (isotretinoin) [ Time Frame: 20 weeks ]
    Change from Baseline to the end of active treatment period (ATP) at week 20 in the acne-specific quality of life (acne-QOL) questionnaire score for those subjects who complete the 20-week ATP and are at least 75% compliant with the treatment regimen (isotretinoin) capsules twice daily without food for the treatment of severe recalcitrant nodular acne


Secondary Outcome Measures :
  1. Change from baseline in the lesion count [ Time Frame: 20 weeks ]
    Change from baseline in the lesion count (nodules and inflammatory lesions) at the end of the ATP.

  2. Change from baseline in the acne-quality of life (QOL) score [ Time Frame: 20 weeks ]
    Change from baseline in the acne-QOL score

  3. Change from baseline in the Investigator's Global Assessment (IGA) [ Time Frame: 20 weeks ]
    Change from baseline in the IGA at the end of the active treatment period in subjects who complete the 20-week active treatment period

  4. Treatment safety (adverse events) [ Time Frame: 20 weeks ]
    Treatment safety as determined by the frequency and severity of adverse events

  5. Treatment safety (local skin irritation) [ Time Frame: 20 weeks ]
    Treatment safety as determined by local skin irritation


Other Outcome Measures:
  1. Primary endpoint for post treatment period (PTP) (Proportion of subjects who require retreatment) [ Time Frame: 104 weeks ]
    Proportion of subjects who require retreatment with oral isotretinoin at any time during post treatment period and the time at which retreatment is required

  2. Secondary endpoint for PTP (Proportion of subjects who require treatment with a prescription anti-acne medication) [ Time Frame: 104 weeks ]
    Proportion of subjects who require treatment with a prescription anti-acne medication other than oral isotretinoin at any point during the PTP

  3. Secondary endpoint for PTP (Proportion of subjects who use an over-the-counter (OTC) anti-acne medication) [ Time Frame: 104 weeks ]
    Proportion of subjects who use an over-the-counter (OTC) anti-acne medication at any time during the PTP

  4. Secondary endpoint for PTP (Severity of acne (lesion count and IGA) [ Time Frame: 104 weeks ]
    Severity of acne (lesion count and IGA) at the time of retreatment in subjects treated with a prescription or OTC anti-acne treatment

  5. Secondary endpoint for PTP (Severity of acne (lesion count and IGA) [ Time Frame: 104 weeks ]
    Severity of acne (lesion count and IGA) at each visit

  6. Secondary endpoint for PTP (Time to retreatment with a prescription or over-the-counter (OTC) anti-acne medication) [ Time Frame: 104 weeks ]
    Time to retreatment with a prescription or over-the-counter (OTC) anti-acne medication at any time during the PTP

  7. Secondary endpoint for PTP (Acne-quality of life) [ Time Frame: 104 weeks ]
    Acne-quality of life at the end of PTP

  8. Secondary endpoint for PTP (monitoring of adverse events, laboratory test results, vital signs, and physical examinations) [ Time Frame: 104 weeks ]
    Safety as assessed through the monitoring of adverse events, laboratory test results, vital signs, and physical examinations



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   12 Years to 45 Years   (Child, Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

General Inclusion Criteria Subjects must meet the following mandatory inclusion criteria at the time of screening to be eligible to enter the study and must agree to conform to the requirements of the study and the iPLEDGE program.

  • Written informed consent, including mandatory photographic consent, on a gender-specific informed consent form (ICF) & Health Insurance Portability and Accountability Act (HIPAA) authorization prior to the performance of any study-related procedures.
  • Pregnant females and females who are not to become pregnant during the ATP phase of the trial and for 30 days after receiving their last dose of study drug.
  • Female subjects of childbearing potential ready to use 2 forms of effective contraception simultaneously for 1 month before starting Absorica® (isotretinoin), while taking Absorica® & for 1 month after Absorica® has been stopped.
  • Male and female subjects of non-childbearing potential

Specific Inclusion Criteria:

  • Severe recalcitrant nodular acne.
  • Five or more nodule lesions on the face.
  • Treatment-naïve subjects.
  • Age between 12 and 45 years.
  • Weight between 40 and 110 kg.
  • Female subjects of childbearing potential only: Negative results from serum pregnancy tests with a sensitivity of at least 25 milli-international unit/mL.
  • Good general health as determined by the investigator based on the subject's medical history, physical examination, vital signs measurements, and laboratory test results.
  • Subjects who present with stable & controlled diabetes mellitus (Types I and II).
  • Subjects with previously diagnosed polycystic ovarian syndrome (PCOS) can be included in the study if in the opinion of the investigator they do not have any other clinically significant abnormality (eg, metabolic syndrome or elevated lipids

Exclusion Criteria:

General Exclusion Criteria

  • Presence of any clinically significant physical examination finding, vital signs measurement, or abnormal laboratory value;
  • Presence of a beard or other facial hair that could interfere with the study assessments;
  • Participated in another clinical trial or received an investigational product within 3 months prior to screening;
  • History of excessive or suspected abuse of alcohol (based on the clinical judgment of the investigator), recreational drugs, and/or drugs of abuse, e.g., club drugs, cocaine, ecstasy/ methylenedioxymethamphetamine, heroin, inhalants, marijuana, methamphetamine, phencyclidine, prescription medications, anabolic steroids, etc.
  • Use of prohibited or restricted prior or concomitant medications. Female Specific Exclusion Criteria
  • Are pregnant;
  • Are at a high risk for becoming pregnant or likely to become pregnant during treatment;
  • Are breast-feeding or considering breast-feeding during the course of the study;
  • Have a known history of PCOS with another clinically significant abnormality (eg, metabolic syndrome or elevated lipids);
  • Are unable or unwilling to maintain compliance with birth control measures

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02457520


Locations
United States, Texas
Texas Dermatology and Laser Specialists
San Antonio, Texas, United States, 78218
Sponsors and Collaborators
Sun Pharmaceutical Industries Limited
Investigators
Study Director: Ashish Anvekar, MD Ranbaxy Laboratories Limited

Responsible Party: Sun Pharmaceutical Industries Limited
ClinicalTrials.gov Identifier: NCT02457520     History of Changes
Other Study ID Numbers: ABS157LT
First Posted: May 29, 2015    Key Record Dates
Last Update Posted: November 5, 2018
Last Verified: November 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Additional relevant MeSH terms:
Isotretinoin
Dermatologic Agents